GLENMARK - Glenmark Pharma.
📢 Recent Corporate Announcements
Glenmark Specialty SA has received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol, a generic version of GSK's FloVent® HFA. The company has been granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant for this product. The target market for this therapy is valued at approximately $520.1 million annually as of January 2026. Commercial distribution in the U.S. is scheduled to begin immediately in March 2026, significantly strengthening Glenmark's respiratory portfolio.
- Received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol (44 mcg)
- Granted 180-day Competitive Generic Therapy (CGT) exclusivity as the first approved applicant
- Targets a market with annual sales of approximately $520.1 million according to IQVIA data
- Commercial launch in the U.S. market is scheduled for March 2026
- Product is bioequivalent and therapeutically equivalent to FloVent® HFA by GlaxoSmithKline
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Sodium Phosphates Injection USP in three single-dose vial presentations. The product is bioequivalent to Hospira's reference drug and is scheduled for distribution starting April 2026. According to IQVIA data, the market for this injection achieved annual sales of approximately $66.8 million for the 12-month period ending December 2025. This launch is part of Glenmark's strategy to expand its product portfolio within the US institutional channel.
- Launch of Sodium Phosphates Injection USP in 15 mM, 45 mM, and 150 mM single-dose vials.
- Distribution in the US market is set to begin in April 2026.
- Targets a market segment with annual sales of approximately $66.8 million as of December 2025.
- Product is bioequivalent and therapeutically equivalent to Hospira, Inc.’s reference listed drug.
- Strengthens Glenmark's presence in the US institutional channel and injectable portfolio.
NSE Sustainability Ratings and Analytics Limited has independently assigned an ESG rating of 68 to Glenmark Pharmaceuticals for the 2025 financial year. The rating was based on publicly available information, as the company did not formally engage the agency for this assessment. This disclosure is made in compliance with SEBI's updated regulations regarding ESG rating disclosures. While the score provides a benchmark for sustainability, it does not impact the company's current financial operations or earnings outlook.
- NSE Sustainability assigned an ESG rating of 68 for the financial year 2025.
- The rating was determined independently using publicly available data without company engagement.
- Disclosure follows SEBI Circular dated November 11, 2024, regarding ESG rating transparency.
- The rating provides a standardized metric for institutional investors focused on ESG criteria.
Glenmark Pharmaceuticals has officially released the transcript of its earnings conference call held on February 2, 2026. The transcript covers the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This document provides a detailed record of management's responses to analyst queries regarding business strategy and financial outlook. It is a standard regulatory filing following the announcement of quarterly results.
- Transcript of the Earnings Call held on February 02, 2026, is now available for public review.
- Covers financial performance and management commentary for Q3 and nine months ended December 31, 2025.
- The filing is in compliance with Regulation 30(6) of SEBI (LODR) Regulations, 2015.
- Provides transparency on analyst interactions and management's future guidance.
Glenmark Pharmaceuticals has announced its participation in four major institutional investor conferences scheduled between February 9 and March 9, 2026. The company will engage with investors at events hosted by Systematix, Axis Capital, Kotak Securities, and Investec in Mumbai. These sessions will include both group and one-on-one physical meetings to discuss business outlooks. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during these interactions.
- Participation in 4 major investor conferences between February 9 and March 9, 2026
- Conferences hosted by Systematix, Axis Capital, Kotak Securities, and Investec
- Meetings will be conducted in physical format in Mumbai
- Engagement includes both group and one-on-one interaction types
- Company confirmed no unpublished price sensitive information will be disclosed
Glenmark Pharmaceuticals has officially released the audio recording of its Q3 FY 2025-26 earnings conference call held on February 02, 2026. This disclosure is in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations. The recording provides a detailed account of management's discussion on the financial performance for the quarter ending December 31, 2025. Investors can access the link on the company's website to understand the strategic outlook and operational updates provided during the session.
- Official audio recording of the Q3 FY 2025-26 earnings call is now available for public access.
- The conference call was conducted on February 02, 2026, following the quarterly financial results announcement.
- Filing made under Regulation 30 and 46 of SEBI LODR Regulations to ensure transparency.
- The recording includes management commentary on business performance and responses to institutional investor queries.
The Goods & Service Tax (GST) Department, Mumbai, conducted a search and seizure operation at the offices of Glenmark Pharmaceuticals from January 27 to January 31, 2026. The inspection was carried out under Section 67 of the Maharashtra GST Act, 2017, and lasted for approximately five days. The company has stated that it fully cooperated with the officials and provided all requested documentation. Currently, no official document regarding adverse findings has been issued, and the company reports no material impact on its financials or operations.
- Search operation conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
- Inspection commenced on January 27, 2026, and concluded on January 31, 2026
- Action initiated under Section 67 of the Maharashtra Goods and Services Tax Act, 2017
- Company reports no material impact on financial or operational activities at this stage
- No official adverse findings or tax demand notices have been issued following the conclusion of the search
Glenmark Pharmaceuticals reported a strong Q3 FY26 with consolidated revenue rising 15.1% YoY to Rs 39,006 Mn, led by a robust 22.1% growth in the India business. The company maintained healthy profitability with an EBITDA margin of 22.3% and a PAT of Rs 4,032 Mn, despite an exceptional charge of Rs 1,843 Mn related to new labor codes. A significant regulatory milestone was achieved with the receipt of an EIR for the Monroe manufacturing site, clearing the path for restarted commercial production. The innovative portfolio continues to scale, with RYALTRIS gaining traction globally and WINLEVI receiving EU approval.
- Consolidated Revenue increased 15.1% YoY to Rs 39,006 Mn with an EBITDA of Rs 8,697 Mn.
- India business grew 22.1% YoY, outperforming the market in Dermatology, Respiratory, and Cardiac segments.
- North America core business grew 4.1% YoY; Monroe site received EIR with VAI status to restart manufacturing.
- Innovative product RYALTRIS received approval in China, while WINLEVI was approved in the EU for a Q1 FY27 launch.
- Reported PAT of Rs 4,032 Mn includes a one-time exceptional impact of Rs 1,843 Mn due to New Labour Codes.
Glenmark Pharmaceuticals reported a strong Q3 FY26 performance with consolidated revenue growing 15.1% YoY to Rs 39,006 Mn. The company achieved a significant 44.9% YoY growth in EBITDA, reaching Rs 8,697 Mn with a healthy margin of 22.3%. Growth was robust across key markets, particularly in India (up 22.1%) and North America (up 24.2%), though the latter included out-licensing income. A major operational milestone was achieved with the US FDA granting VAI status to the Monroe facility, allowing for the restart of commercial manufacturing.
- Consolidated revenue increased 15.1% YoY to Rs 39,006 Mn for Q3 FY26.
- EBITDA surged 44.9% YoY to Rs 8,697 Mn with margins expanding to 22.3% from the previous year.
- India Formulations business grew 22.1% YoY to Rs 12,986 Mn, outperforming the general market growth.
- Received US FDA Establishment Inspection Report (EIR) with VAI status for the Monroe, North Carolina facility.
- North America revenue grew 24.2% YoY to Rs 9,706 Mn, aided by out-licensing income for ISB 2001.
Glenmark Pharmaceuticals reported a consolidated revenue of ₹39,006 million for Q3 FY26, marking a 15.1% increase compared to ₹33,875 million in the same quarter last year. Net profit for the quarter grew by 15.8% YoY to ₹4,032 million, even after accounting for an exceptional loss of ₹1,843 million. These exceptional items primarily relate to a US antitrust settlement with United Healthcare for $11 million and adjustments for new labor codes in India. For the nine-month period, the company showed robust growth with revenue reaching ₹1,32,119 million, up 31.2% YoY.
- Consolidated revenue from operations grew 15.1% YoY to ₹39,006.15 million in Q3 FY26.
- Net profit (PAT) increased to ₹4,032.28 million from ₹3,480.31 million in the previous year's quarter.
- Exceptional items for the quarter totaled ₹1,843.37 million, including a $11 million US antitrust settlement.
- Basic EPS for the quarter stood at ₹14.29, up from ₹12.33 in Q3 FY25.
- Nine-month consolidated revenue reached ₹1,32,119.25 million, a significant jump from ₹1,00,655.33 million YoY.
Glenmark Pharmaceuticals has scheduled its Q3 FY 2026 earnings conference call for Monday, February 02, 2026, at 8:30 AM IST. The management will discuss the company's financial performance for the quarter ended December 31, 2025. Investors can participate via universal dial-in numbers or international toll-free lines for the USA, UK, Singapore, and Hong Kong. A recording of the call will be uploaded to the company's website within 24 hours of the event.
- Earnings call for Q3 FY 2026 results scheduled for February 02, 2026, at 8:30 AM IST
- Universal access numbers provided: +91 22 6280 1298 and +91 22 7115 8199
- International toll-free numbers available for USA (1 866 746 2133) and UK (0 808 101 1573)
- Call recording to be made available on the official website within 24 hours
Glenmark Pharmaceuticals Limited has scheduled a Board of Directors meeting for January 30, 2026, to review and approve the unaudited financial results for the quarter and nine-month period ending December 31, 2025. In compliance with SEBI insider trading regulations, the trading window for designated persons has been closed from December 31, 2025, through February 1, 2026. This is a routine regulatory filing that precedes the official announcement of the company's quarterly financial performance.
- Board meeting scheduled for January 30, 2026, to approve Q3 and 9M results.
- Financial results cover the period ending December 31, 2025.
- Trading window for insiders closed from December 31, 2025, to February 1, 2026.
- The announcement complies with SEBI (LODR) and Insider Trading Regulations.
SES ESG Research Private Limited has independently assigned Glenmark Pharmaceuticals an ESG rating of 71.1 for the 2025 financial year. The company clarified that it did not engage the agency for this rating; instead, the score was derived from publicly available information. This disclosure is in compliance with the SEBI circular dated November 11, 2024, regarding ESG rating disclosures. While the score provides a benchmark for sustainability performance, it is an unsolicited third-party assessment.
- SES ESG Research assigned an ESG score of 71.1 for the F.Y. 2025 period.
- The rating was conducted independently using publicly available data without company engagement.
- Disclosure made pursuant to Regulation 30 of SEBI Listing Regulations and recent 2024 circulars.
- The rating serves as a sustainability benchmark for institutional and ESG-focused investors.
Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP (30 mg/30 mL) Multiple-Dose Vial in the United States. This product is bioequivalent and therapeutically equivalent to the reference drug from BPI Labs, LLC. The launch targets a market with annual sales of approximately $67.6 million as of October 2025. This move is intended to strengthen Glenmark's institutional channel portfolio and its presence in the North American generics market.
- Launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the US market.
- Targets an addressable market size of approximately $67.6 million in annual sales.
- Product is therapeutically equivalent to BPI Labs, LLC’s reference listed drug (NDA 205029).
- Aims to expand the company's footprint within the US institutional channel for injectable products.
Glenmark's subsidiary, GSSA, has entered into an exclusive licensing agreement with Hansoh Pharma for Aumolertinib, a third-generation lung cancer treatment. The deal grants Glenmark rights across the Middle East, Africa, Southeast Asia, Australia, and Russia/CIS. Glenmark will pay a low double-digit million USD upfront, with potential milestone payments exceeding $1 billion plus tiered royalties. This strategic move significantly bolsters Glenmark's oncology portfolio with a drug already approved by the UK MHRA and China's NMPA.
- Exclusive rights for Aumolertinib in Middle East, Africa, SE Asia, Australia, and Russia/CIS.
- Upfront payment of low double-digit million USD to Hansoh Pharma.
- Potential regulatory and commercial milestones totaling over US$1 billion.
- Aumolertinib is a third-generation EGFR-TKI approved for various non-small cell lung cancer indications.
- The drug is already marketed as Ameile in China and Aumseqa in the United Kingdom.
Financial Performance
Revenue Growth by Segment
India formulations grew 32% in FY25 (total revenue INR 13,321 Cr). The US market contracted by 2.5% in FY25. In Q2 FY26, India formulation sales were INR 165 Cr, an 87% decline from INR 1,281.7 Cr due to GST transition impacts. Consolidated revenue for H1 FY26 was INR 9,311.3 Cr, up 39.4% YoY.
Geographic Revenue Split
India (significant contributor with 32% growth in FY25), US (contraction of 2.5% in FY25), Europe and Rest of World (continued traction and growth).
Profitability Margins
Operating profitability improved from 10.1% in FY24 to 17.7% in FY25. Net profit was INR 687 Cr in FY25 compared to a loss of INR 1,686 Cr in FY24. The company targets an EBITDA margin of 23% in H2 FY26 and 25% in the future.
EBITDA Margin
EBITDA margin was 17.7% in FY25, up from 10.1% in FY24. The company aims for 23% in H2 FY26 and 25% long-term, driven by a shift to branded products and licensing income from the AbbVie deal.
Capital Expenditure
Planned annual capital expenditure is INR 700-800 Cr over the medium term to support growth and maintain 10 manufacturing facilities.
Credit Rating & Borrowing
CRISIL AA with a Stable outlook; short-term rating is CRISIL A1+. Ratings were reaffirmed following the USD 700 million AbbVie deal. The company repaid INR 1,300 Cr of gross debt post-deal.
Operational Drivers
Raw Materials
Not disclosed in available documents; however, 'benign input costs' were cited as a key driver for the margin improvement to 17.7% in FY25.
Capacity Expansion
The company currently operates 10 manufacturing facilities across India, the USA, and other countries. While specific MTPA expansion figures are not disclosed, the company plans to incur annual capital expenditure of INR 700-800 Cr over the medium term to support its 15% growth target.
Raw Material Costs
Raw material costs are described as 'benign' and 'stable', contributing to the improvement in operating margins to 17.7% in FY25. Specific cost as a % of revenue is not disclosed.
Manufacturing Efficiency
The company maintains an inventory level of 80 days, which is more efficient than the industry average of 90 days. This efficiency supports the H2 FY26 growth targets and was achieved through a one-time working capital correction of INR 1,600 Cr.
Logistics & Distribution
Distribution costs were impacted by freight and reverse logistics during the GST transition, contributing to the 87% decline in India primary sales in Q2 FY26. The company uses a unique 3-tier distribution system in India.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Glenmark 3.0 strategy targets 15% annual growth through a branded-led portfolio and innovation. The USD 700M AbbVie upfront payment will be used to reach zero debt, improving free cash flow for reinvestment. US growth is expected to revive with new launches, while India continues to outperform the market (10.8% vs 6.4% growth).
Products & Services
Pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs), and innovative assets like ISB 2001 (biologics).
Brand Portfolio
Glenmark, Ichnos Glenmark Innovation (IGI).
New Products/Services
ISB 2001 (partnered with AbbVie) and new US product launches are expected to drive future revenue. The AbbVie deal total value is USD 1.925 billion.
Market Expansion
Expansion is focused on Europe and Rest of World (ROW) markets, alongside a revival of the US market through new product launches.
Market Share & Ranking
Glenmark's India formulation business grew 10.8% in Q2 FY26, significantly outperforming the overall Indian pharma market growth of 6.4%.
Strategic Alliances
Exclusive global licensing deal with AbbVie Inc. for ISB 2001 (total value USD 1.925 billion) and the sale of a majority stake in Glenmark Life Sciences to Nirma Ltd in March 2024.
External Factors
Industry Trends
The industry is shifting toward innovation-led biotech deals (e.g., USD 1.925B AbbVie deal) and branded portfolios (Glenmark 3.0) to achieve 25% margins and offset generic pricing pressure in the US (2.5% contraction).
Competitive Landscape
Key competitors include other large Indian pharma companies. Glenmark competes by outperforming market growth (10.8% vs 6.4%) and moving into innovative biologics to differentiate from generic peers.
Competitive Moat
The company's moat is built on its robust R&D platform, specifically through Ichnos Glenmark Innovation (IGI), which successfully developed ISB 2001. This asset's validation through a USD 1.925 billion deal with AbbVie creates a competitive advantage in the innovative biologics space.
Macro Economic Sensitivity
The business is sensitive to regulatory changes like the GST regime, which caused an 87% temporary drop in India sales. It is also exposed to US market dynamics, where a lack of new launches led to a 2.5% revenue contraction.
Consumer Behavior
Demand is driven by a strong position in the chronic therapeutic segment in India, which is fast-growing and less sensitive to short-term economic shifts than acute segments.
Geopolitical Risks
The company operates 10 facilities globally and exports to developing nations, exposing it to trade barriers and regulatory risks in diverse international markets.
Regulatory & Governance
Industry Regulations
Operations are affected by pricing controls (e.g., INR 900.1 Cr settlement for pricing practices), manufacturing standards across 10 global facilities, and tax regime changes like GST which impacted India sales by 87%.
Environmental Compliance
The company has a board-level ESG committee to monitor its ESG strategy and action plans. Specific compliance costs in INR are not disclosed.
Taxation Policy Impact
The company paid INR 75 Cr in cash tax as part of its Q2 FY26 cash flow reconciliation. It aims for tax efficiencies through balance sheet restructuring.
Legal Contingencies
Exceptional losses of INR 372.8 Cr in FY25 and INR 900.1 Cr in FY24 for legal settlements regarding pricing and other claims. These settlements significantly impact cash generation and debt metrics.
Risk Analysis
Key Uncertainties
Key risks include the uncertain returns on high R&D investments (7% of sales), potential for sluggish business performance impacting the 15% growth target, and further stretch in the working capital cycle.
Geographic Concentration Risk
India formulations (32% growth in FY25) and the US market (-2.5% contraction) are the primary regions. The US market's performance is a key risk factor for overall top-line improvement.
Technology Obsolescence Risk
The company is mitigating technology risks by transitioning to 'Glenmark 3.0', focusing on innovative biologics (ISB 2001) to move up the value chain and avoid the obsolescence of traditional generic manufacturing.
Credit & Counterparty Risk
Receivables quality is being addressed by discontinuing legacy pre-collection practices and taking a one-time INR 1,600 Cr provision for debtors and inventory to ensure the balance sheet reflects true capital efficiency.